A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming
Open Access
- 15 April 2025
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-16
Abstract
Melanoma, being one of the most dangerous forms of skin cancer, is characterized by its aggressive and metastatic nature, with the potential to develop resistance to various treatments. This resistance makes the disease challenging to treat, emphasizing the need for new treatment strategies. Within the tumor microenvironment (TME), melanoma cells exploit metabolic shifts, particularly glycolysis, to create an immunosuppressive TME that prevents dendritic cells (DCs) from functioning properly. Essential metabolic alterations such as lactate and lipid accumulation, and lack of tryptophan disrupt DC maturation, antigen presentation, and T cell activation. In recent years, melanoma immunotherapy has increasingly focused on reprogramming the metabolism of DCs. This review paper aims to provide insights into the metabolic suppression of melanoma-associated DCs, allowing the design of therapeutic strategies based on metabolic interventions to promote or restore DC function. This contribution reviews the metabolic reprogramming of DCs as a new approach for melanoma immunotherapy.Keywords
This publication has 157 references indexed in Scilit:
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and StressMolecular Cell, 2010
- Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activationBlood, 2010
- Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activityCancer Immunology, Immunotherapy, 2010
- Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cellsHuman Immunology, 2009
- Dendritic Cell Subtypes and In Vitro Generation of Dendritic CellsHormone and Metabolic Research, 2008
- Steady-state and inflammatory dendritic-cell developmentNature Reviews Immunology, 2006
- Sensing Environmental Lipids by Dendritic Cell Modulates Its FunctionThe Journal of Immunology, 2004
- Dendritic-cell control of pathogen-driven T-cell polarizationNature Reviews Immunology, 2003
- Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their ApoptosisThe Journal of Immunology, 2003
- Tolerogenic Dendritic CellsAnnual Review of Immunology, 2003